KRAS Somatic Mutation Testing
Over 50% of all colorectal cancers show mutations in one of the RAS genes, KRAS or NRAS of which around 36-40% of the mutations occur in KRAS gene alone. Anti-EGFR monoclonal antibody (cetuximab and panitumumab) therapy is approved and effective only in KRAS “wild type” patients with advanced
colorectal cancers. While guidelines differ regarding when EGFR antibody therapy can be administered, it is getting widely accepted that mutations other than in codon 12 and 13 in KRAS may reduce the
sensitivity of anti-EGFR therapy.
Centogene offers multiple screening tests for KRAS gene to suit the recommendations of different
A. Hot spot targeted mutation testing
c.35G>A/p.G12D (34%), c.35G>T/p.G12V (22%) and c.38G>A/p.G13D (19%) are the most frequent
mutations present in codon 12 and 13 of KRAS gene in colorectal cancers where KRAS gene is found to be mutated. For rapid and sensitive screening of these mutations, Centogene offers quantitative PCR based approach to selectively screen or monitor individual mutations down to 0.05% allele frequency.
B. Full gene testing
Testing of complete coding region of KRAS gene is offered through Next Generation Sequencing that can detect mutations at allele frequency down to 5% in tumor samples.
C. Panel testing
For general screening of somatic mutations, KRAS exons are also a part of broader multi-gene panels like Cancer Hotspots Panel (detects 63 described mutations in KRAS gene along with commonly described mutations in 49 other oncogenes), Myeloid Tumor Panel (covers exon 2 and exon 3 of KRAS along with
selective targeted regions in 53 other oncogenes and tumor suppressor genes involved in hematological malignancies) or Solid Tumor Panel (~93.6% of the coding region of KRAS gene is covered along with over 95% coverage of coding regions of 61 other tumor related genes) that are readily available on Centogene website.
C. Microarray testing
Detection of 11 most important somatic mutations (including c.34G>T/A/C, c.35G>T/A, c.38G>A, c.180_181TC>AA, c.181C>A, c.183A>C/T and c.436G>C) in KRAS at >30% allele frequency is also
supported by our CentoArrayOnco where one can combine detection of selective actionable somatic
mutations with copy number variations across 900 oncogenes and tumor related genes in tumor samples. This array includes apart from KRAS, 63 mutations in 8 other oncogenes.
Please refer to preferred test (s) on our test catalogue or ask our customer relations team for more specific information. We are constantly developing new tests. If your preferred test is not listed on the webpage, please contact us directly. We will be happy to assist you find the best possible solution for your patient.